Exploring Novel Therapeutics for Pulmonary Arterial Hypertension

International Heart Journal, Journal Year: 2025, Volume and Issue: 66(1), P. 3 - 12

Published: Jan. 30, 2025

Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by progressive obliteration of pulmonary arteries. Dysregulated bone morphogenetic protein (BMP) signaling pathway contributes to the development PAH, and vasodilators including endothelin receptor antagonists, phosphodiesterase 5 inhibitors, prostaglandins soluble guanylate cyclase stimulators, dramatically improve long-term prognosis. However, there still exist refractory patients who require continuous catecholamine support or lung transplantation, new treatment strategies targeting molecular mechanisms PAH highly anticipated. Sotatercept, first-in-class activin inhibitor, has recently been approved for it targets restores an imbalance in activin-growth differentiation factor BMP signaling. In addition, peroxisome proliferator-activated receptor-γ signaling, inflammatory immune systems, DNA damage response cellular senescence, growth receptors vascular endothelial platelet-derived receptors, are being devised. this review, we briefly summarize recent advances basic research paving way more effective treatments their potential clinical therapeutic applications.

Language: Английский

---

Shared genetic features inference among hypoxia-ischemia diseases in the presence of heterogenous omics data based on a novel risk assessment method

Frontiers in Genetics, Journal Year: 2025, Volume and Issue: 16

Published: April 28, 2025

The hypoxia-ischemia (H-I) diseases share some common mechanisms which may help to delay the diseases' processing. However, shared features are still unclear due lack of large scale high-quality multi - omics data that specifically target same disease, population, and tissues/cells. In this study, we developed a novel risk assessment method analyze four H-I including eclampsia/preeclampsia (PE), pulmonary arterial hypertension (PAH), high-altitude polycythemia (HAPC), ischemic stroke (IS). A combined new evaluation score was designed integrate information from genomics, transcriptomics, proteomics, metabolomics in previous researches. Genes were then divided into different groups according their score. most significant group (direct biomarkers) contained genes with direct evidence association disease: PIEZO2 HPGD (shared), TSIX SAA1 (PAH specific), GSTM1, DNTT, IGKC (HAPC LEP, SERPINA3, ARHGEF4 (PE CD3D, ITK, RPL18A (IS specific). 'Intermediate crucial biomarkers' played important roles disease related biological processes: CXCL8 HBG2, GRIN2A, FGFBP1 FAM111B C12orf39 SLAMF1 lacking disease-association but similar characteristics above two considered as 'potential minor-effect biomarkers': SRRM2 AS1 ATP8A1 RXFP1 HJURP HIST1H1T With development experiments, these intermediate potential biomarkers be proved future. Therefore, serve an entry point for subsequent research great significance.

Language: Английский

---

Dihydromyricetin Restores Mucus Hypersecretion in Air–Liquid Interface Cultures in COPD by Targeting the SRC-MAPK Signaling Pathway

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177703 - 177703

Published: May 1, 2025

Language: Английский

---

Recent advances and therapeutic applications of PPARγ-targeted ligands based on the inhibition mechanism of Ser273 phosphorylation

Metabolism, Journal Year: 2024, Volume and Issue: 163, P. 156097 - 156097

Published: Dec. 3, 2024

Language: Английский

---